FSTX News and Press, F-star Therapeutics Inc Com From 12/20/22

Summary In my opinion, there is value in lowering portfolio volatility over the long term. You don't need to invest solely in assets with lower volatility to bring portfolio volatility down. Asset classes, factors and even certain stocks can interact with a portfolio in highly benef...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can...

Summary The odds are now in favor of a successful completion of the Sino Biopharmaceutical/F-star merger as the UK government has approved the deal. CFIUS is the final hurdle before the deal can close. While CFIUS approval is not a slam dunk, the latest developments point towa...

- FS118 is Well-Tolerated Across all Dose Levels with No Serious Adverse Events Related to FS118 Therapy - Novel mechanism showing Increased Peripheral Immune Cells and LAG-3 shedding - 54.8% Disease Control Rate in PD-L1 Acquired Resistance Patients at doses > 1m...

F-star Therapeutics ( NASDAQ: FSTX ) planned sale to Sino-Biopharma was withdrawn and refiled with CFIUS. CFIUS’s acceptance of the refiled voluntary notice is effective as of Wednesday, F-star ( FSTX ) said in an 8-K filing. CFIUS will have a review period ...

F-star Therapeutics ( NASDAQ: FSTX ) dropped 3.3% after falling 7% Friday as a deadline for a national security review of its planned sale to Sino-Biopharma ( OTCPK:SBHMY ) is set to expire on Monday. F-star ( FSTX ) disclosed last month that a CFIUS ...

Update 10:20am : Updates shares. F-star Therapeutics ( NASDAQ: FSTX ) pared earlier declines and is now down 1.5% at least partly on investor concern about CFIUS approval for the company's sale to Sino-Biopharma ( OTCPK:SBHMY ). A New York Times article ...

F-star Therapeutics ( NASDAQ: FSTX ) fell 16% in premarket trading at least party on investor concern about CFIUS approval for the company's sale to Sino-Biopharma ( OTCPK:SBHMY ). A New York Times article from Thursday that the U.S. may extend export...

Summary Regulatory approval of F-star Therapeutics, Inc.'s merger is not looking good. FSTX is currently facing significant resistance from the United States Committee on Foreign Investment and the U.K. National Security and Investment Act. While the upside is significant if t...

F-star Therapeutics Inc. ( NASDAQ: FSTX ) dropped 2% after the company disclosed that a national security review of its sale to Sino-Biopharma ( OTCPK:SBHMY ) has moved into an extended review. The CFIUS review of the deal is expected to continue for another 45 day...